[DOI] [PMC free article] [PubMed] [Google Scholar] 10.Wharton S., Davies M., Dicker D., et al
Neuron 98, 10801098
GLP-1 GLP-1GLP-1GLP-1 GLP-1 GLP-1GLP-1 GLP-1 GLP-1GLP-1GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 14mg GLP-1 GLP-1 GLP-11 GLP-1 GLP-1 GLP-1 GLP-1GLP-1 :GLP-1POMC GLP-1: GLP-1 GLP-1 GLP-1GLP-1 1 GLP-1 GLP-1 GLP-1 BMI30-4530 1515312 101kg 35.0kg 101kg3 31GLP-1 -3000kcal 5 Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity 4 GLP-1 11 2 28kg GLP-1 413 GLP-1 GLP-1 GLP-1 2 GLP-1 GLP-1 GLP-1 GLP-1 GLP-1 GI 30 12 1OK GLP-1 GLP-1 GLP-1 1 (1% GLP-1 GLP-1 GLP-1 GLP-1 FIRE CLINIC 1,8000 23,000 GLP-1 GLP-1 Q1GLP-1 GLP-1 2 GLP-1 Q2: GLP-1 GLP-1 BMI27 Q3: GLP-1 GLP-1 GLP-1 EMS() GLP-1GLP-1 FIRE CLINICGLP-1 PROFILE 2017 2017 2019 2020 FIRE CLINIC 2021 2023 4FIRE CLINIC 2024 2026.05.1610 2026.05.168 2026.05.1512 2026.05.1510
Individuals with reduced-function variants may experience greater clinical benefit from supplementation than those with wild-type alleles
Gastrointestinal AEs are a well-established side effect of treatment with GLP-1 receptor agonists [30] and, as expected, gastrointestinal AEs were reported more frequently in subjects treated with OW semaglutide 1.0 mg compared with OW semaglutide 0.5 mg or placebo
Week 9-16: accelerated progress Weeks nine through sixteen represent the steepest part of the weight loss curve for most retatrutide users
